CKD-506 / Chong Kun Dang  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CKD-506 / Chong Kun Dang
NCT04204603: A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate

Completed
2a
122
Europe, RoW
CKD-506, Placebo
Chong Kun Dang Pharmaceutical
Rheumatoid Arthritis
09/19
10/19
2018-001377-24: Not available.

Not yet recruiting
2
120
RoW
CKD-506, Tablet
Chong Kun Dang Pharmaceutical Corporation (CKD), Chong Kun Dang Pharmaceutical Corporation (CKD)
Rheumatoid arthritis (RA), Rheumatoid arthritis, Diseases [C] - Immune System Diseases [C20]
 
 

Download Options